Clinical Trials
50 trialsNCT03745326 2026-05-19
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT04387071 2026-04-17
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
University of Southern California
Phase 1/2 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT04643405 2026-01-08
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT05525286 2025-11-17
CLAUDIO-01
Sotio Biotech Inc.
Phase 1/2 Terminated
NCT05194735 2025-11-10
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Phase 1/2 Terminated
NCT06069778 2025-10-31
Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
BioNTech SE
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01834235 2025-05-07
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Precision Biologics, Inc
Phase 1/2 Terminated
NCT04203641 2025-05-06
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Helix BioPharma Corporation
Phase 1/2 Terminated
NCT03829501 2025-04-02
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Phase 1/2 Terminated
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT04683939 2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
Phase 1/2 Terminated
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT00819169 2024-08-20
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NantCell, Inc.
Phase 1/2 Terminated
NCT06065059 2024-08-13
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT03127098 2024-08-06
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02902484 2024-06-03
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT05716295 2024-05-08
ORCHID-1
Medikine, Inc.
Phase 1/2 Terminated
NCT04808362 2024-04-25
MYCure
Peptomyc S.L.
Phase 1/2 Terminated
NCT03376659 2024-02-05
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Phase 1/2 Terminated
NCT04637698 2023-11-24
OH2 Oncolytic Viral Therapy in Pancreatic Cancer
Binhui Biopharmaceutical Co., Ltd.
Phase 1/2 Terminated
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT03576131 2023-08-01
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Terminated
NCT04327986 2022-05-18
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03637491 2022-01-26
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT01784861 2021-07-08
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Washington University School of Medicine
Phase 1/2 Terminated
NCT03451773 2021-06-16
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02985801 2021-03-15
PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
Mayo Clinic
Phase 1/2 Terminated
NCT02743975 2020-01-28
PENGUIN
University Medical Center Groningen
Phase 1/2 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02352831 2019-08-28
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 1/2 Terminated
NCT01632306 2019-01-15
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Terminated
NCT01621243 2018-08-29
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Momenta Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT02331251 2018-07-02
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Phase 1/2 Terminated
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT00889187 2018-05-11
Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00463840 2017-12-05
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
NYU Langone Health
Phase 1/2 Terminated
NCT00948688 2017-05-10
Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
Massachusetts General Hospital
Phase 1/2 Terminated
NCT00907166 2017-03-21
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Cornerstone Pharmaceuticals
Phase 1/2 Terminated
NCT01693276 2015-10-26
Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
University of Cincinnati
Phase 1/2 Terminated
NCT01042028 2015-10-20
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
Odense University Hospital
Phase 1/2 Terminated
NCT00587132 2013-06-24
Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma
Mayo Clinic
Phase 1/2 Terminated
NCT00410774 2012-09-17
Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery
University of California, San Francisco
Phase 1/2 Terminated
NCT00831493 2012-02-28
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00683085 2011-07-22
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Tokyo University
Phase 1/2 Terminated
NCT00307723 2009-08-10
Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT00179751 2005-11-07
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
Celgene
Phase 1/2 Terminated